GlaxoSmithKline will move its global headquarters to a new £120m site, as the pharmaceutical giant prepares to split up its empire into two separate businesses.
The company today announced plans for a shiny new £120m headquarters in Weybridge for its new independent consumer healthcare company. Remaining pharmaceuticals and vaccine staff will also relocate from the existing head office in Brentford, the company said.
The break-up of GSK, planned for the middle of next year, will see the creation of a separately listed company for the pharmaceutical’s consumer healthcare arm in a joint venture with Pfizer.
The company said that when the split takes place in the middle of 2022 staff will first be moved to temporary offices in Weybridge, where GSK already owns research and development sites.
By the end of 2024 though the firm intends to have completed the new headquarters which will have capacity for around 1,400 staff.